A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
- Registration Number
- NCT03599713
- Lead Sponsor
- Incyte Corporation
- Brief Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 107
- Signed informed consent.
- Diagnosis of MCC with distant metastatic disease or recurrent, advanced locoregional disease not amenable to surgery or radiation
- Eastern Cooperative Oncology Group performance status of 0 to 1.
- Measurable disease according to RECIST v1.1.
- Availability of tumor tissue (fresh or archival) for central pathology review.
- Willingness to avoid pregnancy or fathering children based on protocol-defined criteria.
- Prior systemic therapy for MCC, including chemotherapy and prior PD-1 or PD-L1-directed therapy.
- Treatment with anticancer drugs or participation in another interventional clinical study within 21 days before the first administration of study drug.
- Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy (with the exceptions for anemia not requiring transfusion support and any grade of alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment.
- Radiation therapy administered within 2 weeks of first dose of study treatment or radiation therapy to the thoracic region that is > 30 Gy within 6 months of the first dose of study treatment.
- Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
- History of second malignancy within 3 years (with exceptions).
- Laboratory values outside the protocol-defined range at screening.
- Clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders.
- Active bacterial, fungal, or viral infections, including hepatitis A, B, and C.
- Receipt of a live vaccine within 28 days of planned start of study therapy.
- Current use of protocol-defined prohibited medication.
- Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids).
- Inability or unlikely, in the opinion of the investigator, to comply with the Protocol requirements.
- Participant who is pregnant or breastfeeding.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Retifanlimab: Chemotherapy: Naïve Retifanlimab - Retifanlimab: Chemotherapy: Refractory Retifanlimab -
- Primary Outcome Measures
Name Time Method Objective Response Rate (ORR) up to 26.8 months ORR was defined as the percentage of participants with a confirmed overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1), as determined by Independent Central Radiographic Review (ICR), at any post-Baseline visit until the first progressive disease (PD) or new anti-cancer therapy. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
- Secondary Outcome Measures
Name Time Method Overall Survival up to 33.9 months Overall survival was defined as the time in months between the first dose date (Day 1) and the date of death due to any cause.
First-dose Cmax of Retifanlimab preinfusion, 10 minutes postinfusion (± 10 minutes), and 4 hours postinfusion (± 10 minutes) on Day 1 of Cycle 1 Cmax was defined as the maximum observed plasma concentration.
First-dose AUC0-t of Retifanlimab preinfusion, 10 minutes postinfusion (± 10 minutes), and 4 hours postinfusion (± 10 minutes) on Day 1 of Cycle 1 AUC0-t was defined as the area under the plasma concentration-time curve from time zero to time t.
Duration of Response (DOR) up to 24.9 months DOR was defined as the time from an initial objective response (CR or PR) per RECIST v1.1 until PD, or death due to any cause, as determined by ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. A Kaplan-Meier estimate (estimated median) of the distribution function is reported.
Disease Control Rate (DCR) up to 26.8 months DCR was defined as the percentage of participants with a confirmed overall response (CR and PR) or stable disease (SD) (non-CR/non-PD) lasting at least 6 months from the start of treatment, until the first PD or new anti-cancer therapy, per RECIST v1.1 as determined by ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.
Progression-free Survival (PFS) up to 26.8 months According to RESIST v1.1, PFS was defined the time from the start of therapy until disease progression, or death due to any cause, as determined by ICR. Evaluation of target lesions: PD: ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered PD). Evaluation of non-target lesions: PD: Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered PD).
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) up to 823 days (up to approximately 2.3 years) An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as either an AE reported for the first time or a worsening of a pre-existing event after the first dose of study drug until 90 days after the last dose of study drug. An AE with onset on/after starting a new anticancer therapy was not summarized as a TEAE.
First-dose Cmin of Retifanlimab preinfusion, 10 minutes postinfusion (± 10 minutes), and 4 hours postinfusion (± 10 minutes) on Day 1 of Cycle 1 Cmin was defined as the minimum observed plasma concentration over the dose interval.
Trial Locations
- Locations (65)
Stanford Cancer Institute
🇺🇸Palo Alto, California, United States
Upmc Cancercenter
🇺🇸Pittsburgh, Pennsylvania, United States
Roswell Park Cancer Institute
🇺🇸Buffalo, New York, United States
Chu Hopital de La Timone
🇫🇷Marseille Cedex 5, France
Elbe Klinikum Buxtehude
🇩🇪Buxtehude, Germany
Tom Baker Cancer Centre
🇨🇦Calgary Ab, CA, Canada
St Vincent'S Hospital Sydney
🇦🇺Darlinghurst, New South Wales, Australia
University Hospital Regensburg
🇩🇪Regensburg, Germany
Universitaetsklinikum in Tubingen
🇩🇪Tubingen, Germany
Helios Klinikum Erfurt
🇩🇪Erfurt, Germany
H�PITAL AMBROISE PAR
🇫🇷Boulogne-billancourt, France
Prof Mudr Petr Arenberger Drsc Mba
🇨🇿Praha, Czechia
University of Washington - Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
Hospital Saint Louis
🇫🇷Paris, France
Thomayerova Nemocnice
🇨🇿Praha 4-krc, Czechia
Universitatsklinikum Essen
🇩🇪Essen, Germany
Inova Fairfax Hospital
🇺🇸Fairfax, Virginia, United States
Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu
🇫🇷Nantes Cedex, France
Universitatsklinikum Giessen Und Marburg Gmbh, Klinik Für Innere Medizin
🇩🇪Marburg, Germany
Hospital Clinic I Provincial
🇪🇸Barcelona, Spain
Irccs Azienda Ospedaliera Universitaria San Martino
🇮🇹Genova, Italy
ONCOLOGIA � IDI IRCCS ISTITUTO DERMOPATICO DELL'IMMACOLATA
🇮🇹Rome, Italy
Institut Gustave Roussy
🇫🇷Villejuif Cedex, France
Charite Universitaetsmedizin Berlin - Campus Charite Mitte
🇩🇪Berlin, Germany
Universitatsklinikum Schleswig-Holstein
🇩🇪Kiel, Germany
London Health Sciences Centre Lhsc - South Street Hospital
🇨🇦London, Ontario, Canada
Nemocnice Na Bulovce
🇨🇿Praha, Czechia
Fondazione Del Piemonte Per L'Oncologia Ircc Candiolo
🇮🇹Candiolo, Italy
European Institute of Oncology
🇮🇹Milan, Italy
Royal Cornwall Hospital Truro Sunrise Centre
🇬🇧Truro, United Kingdom
Hospital General Universitario Vall D Hebron
🇪🇸Barcelona, Spain
Iov - Istituto Oncologico Veneto Irccs
🇮🇹Padova, Italy
Hospital General Universitario Gregorio Maranon
🇪🇸Madrid, Spain
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte
🇮🇹Siena, Italy
The Royal Marsden Nhs Foundation Trust
🇬🇧London, United Kingdom
University of California San Francisco Comprehensive Cancer Center
🇺🇸San Francisco, California, United States
The Christ Hospital
🇺🇸Cincinnati, Ohio, United States
Rutgers Cancer Institute of Nj
🇺🇸New Brunswick, New Jersey, United States
Universitatsspital Zurich
🇨🇭Zuerich, Switzerland
Centrum Onkologii - Instytut Im. Marii Sklodowskiej - Curie
🇵🇱Warsaw, Poland
John Theurer Cancer Center, Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
Centre Hospitalier Universitaire Vaudois (Chuv)
🇨🇭Lausanne, Switzerland
National Institute of Oncology
🇭🇺Budapest, Hungary
Sir Mortimer B. Davis Jewish General Hospital Segal Cancer Ctr
🇨🇦Montreal, Quebec, Canada
McGill University Health Centre/Glen Site/Cedars Cancer Centre
🇨🇦Montreal, Quebec, Canada
Szte Borgyogyszati Es Allergologiai Klinika
🇭🇺Szeged, Hungary
West Virginia University Hospitals Inc
🇺🇸Morgantown, West Virginia, United States
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Debreceni Egyetem Klinikai Kozpon Belgyogy Klinika
🇭🇺Debrecen, Hungary
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari
🇮🇹Bari, Italy
Fondazione Irccs Istituto Nazionale Dei Tumori
🇮🇹Milan, Italy
A.O.U. Di Modena - Policlinico
🇮🇹Modena, Italy
Istituto Nazionale Tumori Irccs Fondazione Pascale
🇮🇹Naples, Italy
HOPITAL CHARLES NICOLLE CHU ROUEN - H�PITAL DE BOIS-GUILLAUME
🇫🇷Rouen, France
University of Rochester Medical Center
🇺🇸Rochester, New York, United States
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
Rush University
🇺🇸Chicago, Illinois, United States
Mayo Clinic Rochester
🇺🇸Rochester, Minnesota, United States
Fakultni Nemocnice Olomouc
🇨🇿Olomouc, Czechia
CHU DE NICE - H�PITAL L'ARCHET 1
🇫🇷Nice Cedex 3, France
The Royal Marsden Nhs Foundation Trust - Sutton
🇬🇧Sutton, United Kingdom
Norton Cancer Institute
🇺🇸Louisville, Kentucky, United States
Royal Free London Nhs Foundation Trust
🇬🇧London, United Kingdom
Castle Hill Hospital
🇬🇧Cottingham, United Kingdom